In this livestream, Dave breaks down new phase 3 retatrutide data, carefully contrasting idealized trial “efficacy estimate” numbers with more realistic “treatment regimen” outcomes, and explores what this means for real-world obesity care, dosing, and future multi-pathway combinations. He then shifts to news on high-dose Wegovy, safety concerns and fast-tracking of the oral GLP-1 orforglipron, and a detailed critique of the proposed Safe Drug Act of 2025, urging viewers to oppose it via a petition at otplinks.com because of its potential impact on access to compounded obesity medications.